Bio-Rad Laboratories (BIO) Gains from Investment Securities (2010 - 2026)

Bio-Rad Laboratories (BIO) has 17 years of Gains from Investment Securities data on file, last reported at $33.3 million in Q1 2026.

• On a quarterly basis, Gains from Investment Securities rose 104.29% year-over-year to $33.3 million in Q1 2026; TTM through Mar 2026 was $98.0 million, a 13.16% increase from a year earlier, with the FY2025 full-year figure at $81.0 million, down 5.92% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $33.3 million, up from $18.3 million in the prior quarter.
• Over the last five years, Gains from Investment Securities for BIO reached as high as $50.8 million in Q2 2023 and fell as low as $9.4 million in Q3 2022.
• Historically, Gains from Investment Securities has averaged $21.7 million across 5 years, with a median of $18.3 million in 2023.
• Across the five-year window, Gains from Investment Securities jumped 390.08% in 2022 and plunged 30.65% in 2024, its largest moves.
• Year by year, Gains from Investment Securities stood at $17.0 million in 2022, then advanced by 7.77% to $18.3 million in 2023, then gained by 3.98% to $19.0 million in 2024, then fell by 3.68% to $18.3 million in 2025, then surged by 81.97% to $33.3 million in 2026.
• Per Business Quant data, the three most recent Gains from Investment Securities figures were $33.3 million in Q1 2026, $18.3 million in Q4 2025, and $13.8 million in Q3 2025.